Mereo BioPharma Group plc announced the appointment of Wills Hughes-Wilson as Head of Patient Access and Commercial Planning. In her role, Ms. Hughes-Wilson will be responsible for leading and optimizing Mereo's patient access and commercialization strategies, initially in a part-time role as the company builds out its rare disease commercial infrastructure. Most recently, Ms. Hughes-Wilson served on the Executive Leadership Team as Chief Patient Access Officer and Senior Vice President Access & External Affairs at Swedish Orphan Biovitrum. In her role, Ms. Hughes-Wilson was responsible for Sobi's go-to-market commercialization approach and led the pricing, reimbursement and access teams for Sobi's rare disease product portfolio. Prior to joining Sobi, Ms. Hughes-Wilson served as Vice President of Health and Market Access Policy at Genzyme Corporation.